Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Progenitor Cell Mobilisation

Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma

Bone Marrow Transplantation volume 28, pages 923–927 (2001)Cite this article

Abstract

The mobilizing potential and therapeutic activity of ifosfamide/vinorelbine-containing regimens with G-CSF support were explored in patients with pretreated malignant lymphomas. Ten patients with non-Hodgkin's lymphoma (NHL) received ifosfamide and vinorelbine, and 17 with Hodgkin's disease (HD) received ifosfamide, vinorelbine and gemcitabine (IGEV regimen), as induction chemotherapy before high-dose chemotherapy (HDT) with peripheral blood stem cell (PBSC) support. Most of the patients had been heavily pretreated with various chemotherapy regimens ± radiotherapy. The target yield was ⩾3 × 106 CD34+ cells/kg of body weight in order to support the subsequent myeloablative chemotherapy. The optimal PBSC harvest occurred on days 11 and 12, with no difference in CD34+ cell mobilization kinetics between the ifos- famide/vinorelbine and IGEV regimens. The median number of CD34+ cells/kg body weight collected was 10.9 × 106 (range 1.76–61.1 × 106). The median total CD34+ cell/μl, CFU-GM and white blood cells (WBC) for all individual collections was 81.5/μl, 10 × 104/kg, and 17 900/μl, respectively. The target yield of CD34+ cells was reached in 24 of 27 patients. Hematological side-effects were acceptable and no treatment-related hospitalizations or toxic deaths occurred. Fifteen patients have so far received high-dose therapy and PBSC reinfusion with rapid engraftment. These results confirm that ifosfamide and vinorelbine-based chemotherapy regimen with G-CSF support can be successfully and safely used to mobilize PBSCs. Bone Marrow Transplantation (2001) 28, 923–927.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial Lancet 1993 341: 1051–1054

    Article  CAS  PubMed  Google Scholar 

  2. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma New Engl J Med 1995 333: 1540–1545

    Article  CAS  PubMed  Google Scholar 

  3. Schmitz N, Linch DC, Dreger P et al. Randomized trial of filgrastim peripheral progenitor cell transplantation vs autologous bone marrow transplantation in lymphoma patients Lancet 1996 347: 353–357

    Article  CAS  PubMed  Google Scholar 

  4. To LB, Roberts MM, Haylock DN et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants Bone Marrow Transplant 1992 9: 277–284

    CAS  PubMed  Google Scholar 

  5. Shipp MA, Abeloff MD, Antman G et al. International consensus conference on high-dose therapy with hemopoietic stem cell transplantation in aggressive non-Hodgkin's lymphoma: report of the jury J Clin Oncol 1999 17: 423–429

    Article  CAS  PubMed  Google Scholar 

  6. Desikan KR, Jagannath S, Vesole D et al. Collection of peripheral blood stem cell mobilisation (PBSC) in multiple myeloma following G-CSF with or without high-dose cyclophosphamide Blood 1995 86 (Suppl. 1): 1594

    Google Scholar 

  7. Janssen WE, Hiemenz J, Zorsky J et al. Mobilisation of peripheral blood stem cells: comparing cell collections from cyclophosphamide and growth factor based regimens Exp Hematol 1993 21: 567

    Google Scholar 

  8. Vahdat L, Raptis G, Fennelly D et al. Superiority of high-dose cyclophosphamide + G-CSF versus either lower dose cyclophosphamide + G-CSF or G-CSF alone in mobilisation of peripheral blood progenitor cells (PBSCs) Blood 1993 82 (Suppl. 1): 2558

    Google Scholar 

  9. Zeller W, Gutensohn K, Stockschlader M et al. Increase of mobilised CD34-positive peripheral blood progenitor cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and cancer of testis Bone Marrow Transplant 1996 17: 709–713

    CAS  PubMed  Google Scholar 

  10. Cesana C, Regazzi E, Garau D et al. Clonogenic potential and phenotypic analysis of CD34+ cells mobilised by different chemotherapy regimens Haematologica 1999 84: 771–778

    CAS  PubMed  Google Scholar 

  11. Cesana C, Carlo-Stella C, Regazzi E et al. CD34+ cells mobilised by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilised by G-CSF Bone Marrow Transplant 1998 21: 561–568

    Article  CAS  PubMed  Google Scholar 

  12. Benchekroun S, Chouffai Z, Harif M et al. Clinical study of Navelbina activity in Hodgkin's disease. Phase II study. In: Fabre P (ed.) Navelbine (Vinorelbine): Update and New Trends J Libbey: Paris 1991 pp 261–264

    Google Scholar 

  13. Eghabali H . Phase II study of vinorelbine (Navelbine) in previously treated Hodgkin's disease and non-Hodgkin's lymphoma. In: Fabre P (ed.) Navelbine (Vinorelbine): Update and New Trends J Libbey: Paris 1991 pp 253–260

    Google Scholar 

  14. Devizzi L, Santoro A, Bonfante V et al. Vinorelbine: an active drug in the management of patients with heavily pre-treated Hodgkin's disease Ann Oncol 1994 5: 817–820

    Article  CAS  PubMed  Google Scholar 

  15. Devizzi L, Santoro A, Bonfante V et al. Vinorelbine: a new promising drug in Hodgkin's disease Leuk Lymphoma 1995 18: 179–184

    Article  Google Scholar 

  16. Fermè C, Oberlin O, Bouabdallah K et al. Methil-Gag, ifosfamide, navelbine, etoposide (MINE) as salvage therapy for refractory or relapsed Hodgkin's disease (HD) Proc Am Soc Clin Oncol 1991 10: 278a

    Google Scholar 

  17. Fermè C, Bastion Y, Lepage E et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease Ann Oncol 1995 6: 543–549

    Article  PubMed  Google Scholar 

  18. Bonfante V, Viviani S, Santoro A et al. Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease Br J Haematol 1998 103: 533–553

    Article  CAS  PubMed  Google Scholar 

  19. Santoro A, Bredenfeld H, Devizzi L et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study J Clin Oncol 2000 18: 2615–2625

    Article  CAS  PubMed  Google Scholar 

  20. Balzarotti M, Magagnoli M, Castagna L et al. IGEV chemotherapy and consolidation with peripheral blood stem cell transplantation (PBSCT) for refractory-relapsed Hodgkin's disease (HD) Proc Am Soc Clin Oncol 2001 20: 293a

    Google Scholar 

  21. Ozer H, Armitage JO, Bennet CL et al. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines J Clin Oncol 2000 18: 3558–3566

    Article  CAS  PubMed  Google Scholar 

  22. Watts MJ, Sullivan AM, Jamieson E et al. Progenitor cell mobilisation after low dose cyclophosphamide and granulocyte colony stimulating factor; an analysis of progenitor cell quantity and quality and factors predicting for these parameters in 101 pre-treated patients with malignant lymphoma J Clin Oncol 1997 15: 535–546

    Article  CAS  PubMed  Google Scholar 

  23. Baars JW, Holtkamp MJ, Nooyen WJ et al. Mobilisation of blood progenitor cells with ifosfamide and etoposide (VP-16) in combination with recombinant human G-CSF (filgrastim) in patients with malignant lymphomas or solid tumors Anticancer Res 1996 16: 3089–3095

    CAS  PubMed  Google Scholar 

  24. McQuacker G, Haynes AP, Stainer C et al. Stem cell mobilisation in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosfamide, etoposide and epirubicin compared to intermediate dose of cyclophosphamide Br J Haematol 1997 98: 228–223

    Article  Google Scholar 

  25. Fermè C, Brice P, Gabarre J et al. MINE chemotherapy plus RhGMCSF as salvage and peripheral blood progenitor cell mobilising regimen for relapsed or refractory Hodgkin's disease Blood 1994 84 (Suppl. 1): 635

    Google Scholar 

  26. Aurlien E, Holte H, Pharo A et al. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma Bone Marrow Transplant 1998 21: 873–878

    Article  CAS  PubMed  Google Scholar 

  27. Petit J, Boquè C, Cancelas JA et al. Feasibility of ESHAP + G-CSF as peripheral blood hematopoietic progenitor cell mobilisation regimen in resistant and relapsed lymphoma: a single–center study of 22 patients Leuk Lymphoma 1999 34: 119–127

    Article  CAS  PubMed  Google Scholar 

  28. Moskowitz CH, Bertino JR, Glassman JR et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma J Clin Oncol 1999 17: 3776–3785

    Article  CAS  PubMed  Google Scholar 

  29. Weaver CH, Schwartzberg L, Li W et al. High-dose chemotherapy and autologous peripheral blood progenitor cell transplants for the treatment of Hodgkin's disease Bone Marrow Transplant 1996 17: 715–731

    CAS  PubMed  Google Scholar 

  30. Jacquy C, Soree A, Lambert F et al. A quantitative study of PBSC contamination in diffuse large-cell non-Hodgkin's lymphoma: one-half of patients significantly mobilise malignant cells Br J Haematol 2000 110: 631–639

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy

    M Magagnoli, B Sarina, M Balzarotti, L Castagna, I Timofeeva, A Nozza, A Bertuzzi, L Siracusano & A Santoro

  2. Department of Transfusion Medicine and Hematology, Ospedale San Paolo, Milan, Italy

    M Sinnone

Authors
  1. M Magagnoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B Sarina
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Balzarotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L Castagna
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I Timofeeva
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Nozza
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Bertuzzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L Siracusano
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M Sinnone
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A Santoro
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Magagnoli, M., Sarina, B., Balzarotti, M. et al. Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma. Bone Marrow Transplant 28, 923–927 (2001). https://doi.org/10.1038/sj.bmt.1703265

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703265

Keywords

This article is cited by

Search

Advanced search

Quick links